StereotaxisSTXS +3.70%66 FCF Yield % is -9.40 as of Jun. 26, 2026. GuruFocus rates STXS with a GF Score™ of 66/100 and a GF Value™ of $2.31 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Stereotaxis ranks worse than 73.8% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Stereotaxis FCF Yield % Related Terms
Stereotaxis FCF Yield % Historical Data
* Premium members only.
The historical data trend for Stereotaxis's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Stereotaxis's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stereotaxis FCF Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stereotaxis's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Stereotaxis's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stereotaxis (STXS) has a FCF Yield % of -9.40 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Stereotaxis and its competitors. According to the industry distribution chart, Stereotaxis ranks #631 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 73.8%.
Is Stereotaxis' FCF Yield % too high?
Stereotaxis' current FCF Yield % is -9.40. Based on the distribution chart, Stereotaxis ranks #631 out of 855 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Stereotaxis has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stereotaxis' FCF Yield % compare to EMBC and KRMD?
According to the Medical Devices & Instruments industry distribution chart, Stereotaxis ranks #631 out of 855 companies for FCF Yield %. This places Stereotaxis in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Devices & Instruments company?
A good FCF Yield % depends on the Medical Devices & Instruments industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Stereotaxis and its competitors. Stereotaxis's current FCF Yield % is -9.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stereotaxis stock overvalued right now?
Based on GuruFocus' analysis, Stereotaxis (STXS) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.31, compared to a current price of $1.68 — trading 27.3% below its estimated fair value. The current FCF Yield % is -9.40. Stereotaxis' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Stereotaxis (STXS), the current FCF Yield % is -9.40 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stereotaxis (STXS) Overvalued in 2026?
Based on GuruFocus' analysis, Stereotaxis stock appears to be undervalued.
The current stock price of $1.68 is trading 27.3% below its estimated GF Value™ of $2.31.
GuruFocus considers Stereotaxis to be Modestly Undervalued.
Key valuation signals for STXS:
FCF Yield %: -9.40
GF Value™: $2.31 vs. price of $1.68 (27.3% below fair value)
No single metric tells the full story. See the STXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems, Disposables, Royalty, and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
66GF Score
Get the complete analysis for STXS
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STXS has been successfully added to your 
